NASDAQ:OCXOncoCyte Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OncoCyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.78 +0.29 (+11.65 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$2.33Now: $2.78▼$2.9250-Day Range$2.10MA: $2.48▼$2.9152-Week Range$1.50Now: $2.78▼$4.90Volume570,300 shsAverage Volume286,486 shsMarket Capitalization$186.87 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsHeadlinesOptions ChainSocial Media OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for OncoCyte. Previous Next 2.3 Community Rank Outperform VotesOncoCyte has received 17 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOncoCyte has received 20 “underperform” votes. (Add your “underperform” vote.)Community SentimentOncoCyte has received 54.05% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote “Outperform” if you believe OCX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCX Previous Symbol CUSIPN/A CIKN/A Webwww.oncocyte.com Phone510-775-0515Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees16 Outstanding Shares67,218,000Market Cap$186.87 million Next Earnings Date8/12/2020 (Estimated) OptionableOptionable NASDAQ:OCX Rates by TradingView Receive OCX News and Ratings via Email Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. OncoCyte (NASDAQ:OCX) Frequently Asked Questions How has OncoCyte's stock been impacted by COVID-19 (Coronavirus)? OncoCyte's stock was trading at $2.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OCX stock has increased by 29.9% and is now trading at $2.78. View which stocks have been most impacted by Coronavirus. When is OncoCyte's next earnings date? OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for OncoCyte. How were OncoCyte's earnings last quarter? OncoCyte Corporation (NASDAQ:OCX) announced its earnings results on Wednesday, March, 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.06. View OncoCyte's earnings history. Has OncoCyte been receiving favorable news coverage? Press coverage about OCX stock has trended very positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OncoCyte earned a news impact score of 4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutOncoCyte. Who are some of OncoCyte's key competitors? Some companies that are related to OncoCyte include PureTech Health (PRTC), Bellus Health (BLU), CEL-SCI (CVM), Oxford BioMedica (OXB), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), ProMetic Life Sciences (PLI), IMV (IMV) and Medicenna Therapeutics (MDNA). View all competitors. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include LYFT (LYFT), Alibaba Group (BABA), Dropbox (DBX), InVitae (NVTA), T2 Biosystems (TTOO), Slack (WORK), Acasti Pharma (ACST), Aileron Therapeutics (ALRN), Canopy Growth (CGC) and Delta Air Lines (DAL). Who are OncoCyte's key executives? OncoCyte's management team includes the following people: Mr. William Annett, Pres, CEO & Director (Age 65)Mr. Mitchell S. Levine, Chief Financial OfficerDr. Lyndal K. Hesterberg, Chief Scientific OfficerMr. Albert P. Parker II, Chief Operating OfficerDr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66) What is OncoCyte's stock symbol? OncoCyte trades on the NASDAQ under the ticker symbol "OCX." How do I buy shares of OncoCyte? Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is OncoCyte's stock price today? One share of OCX stock can currently be purchased for approximately $2.78. How big of a company is OncoCyte? OncoCyte has a market capitalization of $186.87 million. OncoCyte employs 16 workers across the globe. What is OncoCyte's official website? The official website for OncoCyte is www.oncocyte.com. How can I contact OncoCyte? The company can be reached via phone at 510-775-0515. This page was last updated on 5/25/2020 by MarketBeat.com Staff
